New Key Statistics Module, Z-Score and F-Score
NAS:APRE Key Ratios
| Market Cap $ M | 9.74 |
| Enterprise Value $ M | -31.49 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 0.25 |
| Price/Sales | -- |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | -- |
| EPS (TTM) $ | -1.08 |
| Beneish M-Score | 0 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | 51.70 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | 2.38 |
| EV-to-EBITDA | 2.39 |
| PEG | -- |
| Shares Outstanding M | 12.59 |
| Net Margin (%) | -- |
| Operating Margin % | -- |
| Pre-tax Margin (%) | -- |
| Quick Ratio | 13.56 |
| Current Ratio | 13.56 |
| ROA % (ttm) | -44.76 |
| ROE % (ttm) | -52.67 |
| ROIC % (ttm) | -1,428.48 |
| Dividend Yield % | -- |
| Altman Z-Score | -- |
APRE Number of Guru Trades
APRE Volume of Guru Trades
Gurus Latest Trades with NAS:APRE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:APRE is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Aprea Therapeutics Inc Insider Transactions
No Available Data
News about NAS:APRE
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers